Market Overview

UPDATE: Credit Suisse Reiterates Outperform Rating, Raises PT on Biogen Idec

Related BIIB
AC Immune Is An Alzheimer's Pure Play With A Lot On The Line
John Stumpf And 15 Major CEO Departures In 2016
Best Near-Term Price Gains Ahead For: Established Biotechnology Stocks (Seeking Alpha)

In a report published Monday, Credit Suisse reiterated its Outperform rating on Biogen Idec (NASDAQ: BIIB), and raised its price target from $165.00 to $175.00.

Credit Suisse noted, “We now model BG12 2018 peak revenues of $4.0B (previously $3.0B). As a direct consequence we have increased our out year revenue and EPS estimates by around 27% and 30%, respectively, and our TP to $175 (previously $165). Our modeling work further strengthens our view that BG12 could revolutionize (rather than evolve) the MS market and see further putative upside to our BG12 estimates. We will be attending ECTRIMS this week to further research the assumptions behind our global MS modeling (and obviously test out the restaurants in the gastronomic capital of France).”

Biogen Idec closed on Friday at $152.53.

Latest Ratings for BIIB

Oct 2016JefferiesMaintainsHold
Sep 2016JefferiesDowngradesBuyHold
Aug 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Analyst Ratings


Related Articles (BIIB)

View Comments and Join the Discussion!